Literature DB >> 35601964

Impact of neurofibromatosis type 1 in an adult community population.

Timothy A Gregory1, Peter Simon B Molina1, Gregory D Phillips2, John W Henson3.   

Abstract

Background: Neurofibromatosis type 1 (NF1) is a common tumor predisposition syndrome with varying manifestations and severity. Adult NF1 patients often experience fragmented care, so we sought to characterize the health and demographic features of a community-based population of adults with NF1 and hypothesized that lack of a specialty clinic for adult NF1 patients correlates with unmet needs.
Methods: Retrospective case-control study of all adult cases of NF1 among 4.06 million medical records in a Pacific Northwest population. 122 case charts were reviewed to ascertain NF1 disease features, comorbidities, and severity of disease. A 1:1 control cohort was selected by matching case/control by age, sex, and ZIP code to compare demographic features and health status.
Results: Adult NF1 patients were less likely to have private insurance, be employed, and have children, but were equally likely to be married. One half of cases had disease features compromising health and well-being, and care involved 26 different specialties. Excluding neurofibromas, 43% of cases had cancer compared to 10% of controls [P < .0001, OR 5.38 (2.53-11.4)]. Only 27% of women ages 30-50 had undergone age-appropriate enhanced breast cancer surveillance. Behavioral health problems were found in 60% of NF1 patients compared to 37% of controls [P < .001, OR 2.61 (1.52-4.50)]. 93% of cases referred to a NF1 specialty center underwent a change in management upon establishing care. Conclusions: NF1 patients may benefit from coordinated management of care in a specialty center. Published by Oxford University Press 2022.

Entities:  

Keywords:  burden of disease; epidemiology; neurofibromatosis type 1; quality of life; tumor predisposition

Year:  2022        PMID: 35601964      PMCID: PMC9113236          DOI: 10.1093/nop/npac014

Source DB:  PubMed          Journal:  Neurooncol Pract        ISSN: 2054-2577


  12 in total

Review 1.  An update on the central nervous system manifestations of neurofibromatosis type 1.

Authors:  J Stephen Nix; Jaishri Blakeley; Fausto J Rodriguez
Journal:  Acta Neuropathol       Date:  2019-04-08       Impact factor: 17.088

2.  Incidence and mortality of neurofibromatosis: a total population study in Finland.

Authors:  Elina Uusitalo; Jussi Leppävirta; Anna Koffert; Sakari Suominen; Jussi Vahtera; Tero Vahlberg; Minna Pöyhönen; Juha Peltonen; Sirkku Peltonen
Journal:  J Invest Dermatol       Date:  2014-10-29       Impact factor: 8.551

3.  Impact of neurofibromatosis 1 on Quality of Life: a cross-sectional study of 176 American cases.

Authors:  Patricia Z Page; Grier P Page; Emmanuel Ecosse; Bruce R Korf; Alain Leplege; Pierre Wolkenstein
Journal:  Am J Med Genet A       Date:  2006-09-15       Impact factor: 2.802

Review 4.  Guidelines for the diagnosis and management of individuals with neurofibromatosis 1.

Authors:  Rosalie E Ferner; Susan M Huson; Nick Thomas; Celia Moss; Harry Willshaw; D Gareth Evans; Meena Upadhyaya; Richard Towers; Michael Gleeson; Christine Steiger; Amanda Kirby
Journal:  J Med Genet       Date:  2006-11-14       Impact factor: 6.318

5.  Uptake of health monitoring and disease self-management in Australian adults with neurofibromatosis type 1: strategies to improve care.

Authors:  H A Crawford; B Barton; M J Wilson; Y Berman; V J McKelvey-Martin; P J Morrison; K N North
Journal:  Clin Genet       Date:  2015-07-07       Impact factor: 4.438

6.  Increasing access to specialty care for rare diseases: a case study using a foundation sponsored clinic network for patients with neurofibromatosis 1, neurofibromatosis 2, and schwannomatosis.

Authors:  Vanessa L Merker; Annie Dai; Heather B Radtke; Pamela Knight; Justin T Jordan; Scott R Plotkin
Journal:  BMC Health Serv Res       Date:  2018-08-29       Impact factor: 2.655

7.  Evaluation of QoL in neurofibromatosis patients: a systematic review and meta-analysis study.

Authors:  Akram Sanagoo; Leila Jouybari; Fatemeh Koohi; Fatemeh Sayehmiri
Journal:  BMC Neurol       Date:  2019-06-12       Impact factor: 2.474

8.  The impact of the COVID-19 pandemic on neurofibromatosis clinical care and research.

Authors:  Heather B Radtke; Bonita P Klein-Tasman; Vanessa L Merker; Pamela Knight; Nicole J Ullrich; Justin T Jordan; Bruce Korf; Scott R Plotkin
Journal:  Orphanet J Rare Dis       Date:  2021-02-01       Impact factor: 4.123

9.  Comparing reliability of ICD-10-based COVID-19 comorbidity data to manual chart review, a retrospective cross-sectional study.

Authors:  Joseph W Schaefer; Joshua M Riley; Michael Li; Dianna R Cheney-Peters; Chantel M Venkataraman; Chris J Li; Christa M Smaltz; Conor G Bradley; Crystal Y Lee; Danielle M Fitzpatrick; David B Ney; Dina S Zaret; Divya M Chalikonda; Joshua D Mairose; Kashyap Chauhan; Margaret V Szot; Robert B Jones; Rukaiya Bashir-Hamidu; Shuji Mitsuhashi; Alan A Kubey
Journal:  J Med Virol       Date:  2021-12-08       Impact factor: 20.693

10.  Burden of adult neurofibromatosis 1: development and validation of a burden assessment tool.

Authors:  Marie-Laure Armand; Charles Taieb; Aline Bourgeois; Mireille Bourlier; Mohammed Bennani; Christine Bodemer; Pierre Wolkenstein
Journal:  Orphanet J Rare Dis       Date:  2019-05-03       Impact factor: 4.123

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.